SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes.

Sincalide (CCK-8) is a 8-amino acid C-terminal fragment of cholecystokinin.

Simotinib (SIM-6802) is a novel potent EGFR inhibitor for treatment of NSCLC..

Simmiparib is a novel potent, orally active PARP1/2 inhibitor with IC50 of 1.75/0.22 nM, inhibits PARP1 >90-fold more potently than the other PARPs (PARP3, TNKS1, TNKS2).

Simeprevir (TMC 435350) is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).

Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.

Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.

Sildenafil Mesylate is a mesylate form of Sildenafil, an inhibitor of Phosphodiesterase 5.

Sigma1-IN-4 is a novel small molecule sigma-1 receptor inhibitor with Ki of 38 nM.

SIG1459 (SIG-1459) is a novel anti-acne isoprenylcysteine (IPC) small molecule that shows direct antibacterial activity and inhibits TLR2 inflammatory signaling.

SIG-1191 (SIG1191) is a soprenylcysteine (IPC) small molecule with anti-inflammatory activity, inhibits UVB-induced inflammation blocking pro-inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production.

SHR3824 is a potent, selective SGLT2 inhibitor with IC50 of 2.38 nM, >1000-fold selectivity over SGLT1.

SHP836 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 12 uM (SHP2 1-525), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM).downregulates DUSP6 mRNA, a downstream MAPK pathway marker, in KYSE-520 cancer cells.

SHP389 (SHP-389, SHP 389) is a novel potent, selective, allosteric SHP2 inhibitor with IC50 of 36 nM, shows with impressive hERG selectivity (IC50>30 uM).

SHP2-IN-2 is a selective, allosteric inhibitor of protein tyrosine phosphatase SHP2, preferentially inhibits SHP2 F285S over the PTP domain and allosteric site mutant.

SHP244 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 60 uM (SHP2 1-525), equipotent on the double mutant (SHP2T253M/Q257L IC50=68 uM), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM)..

SHP2 inhibitor LY6 (LY6) is a small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2, inhibits SHP2 with IC50 of 9.8 uM, 7-fold selectivity over SHP1.

SHP2 inhibitor 9 is a potent, selective inhibitor of SHP2 with IC50 of 48 nM, inhibits p-ERK in KYSE520 cells with IC50 of 28 nM.

SHP2 inhibitor 8 is a potent, selective inhibitor of SHP2 with IC50 of 5 nM, inhibits p-ERK in KYSE520 cells with IC50 of 5 nM.

SHP2 inhibitor 14 is a novel potent, selective, allosteric, orally acitve SHP2 inhibitor with IC50 of 28 nM.

Shield-1 analog is a derivative of Shield-1,a cell-permeable FKBP ligand that is designed to protect an otherwise unstable protein domain from degradation; binds tightly to FKBP, induces rapid and processive degradation of the LID domain.

SGPL1-IN-28 is a novel S1P lyase inhibitor with in vitro IC50 of 120 nM, cell IC50 of 230 nM..

SGD-1882 (PBD dimer, Pyrrolobenzodiazepine dimer) is a novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs)..

SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively, IC50 of 0.26 uM (MLLT1).

SG85 is a potent Enterovirus 3C protease inhibitor with EC50 of 180 nM against EV71 and 60 nM against human rhinovirus 14 in a live virus-cell-based assay.

SG3199 is a PBD dimer warhead component of antibody-drug conjugate (ADC) payload tesirine, demonstrates potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with mean GI50 of 151.5 pM.

SFV785 (SRPIN-785) is a derivative of SRPIN340 that selectively inhibits NTRK1 and MAPKAPK5 kinase, shows anti-viral activity on HCV, DENV and yellow fever viruses.

SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.

SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.

Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.